LuciQuiza (Quizartinib)

Inquire / Price
  • Model Number:
    RL3120250101
  • Brand Name:
    LuciQuiza
  • Origin:
    Generic drug,Laos
  • Small Orders:
    Small batches also available
  • Tags:
Inquire Now Link

Poster
  • Details
  • Description
  • Packaging Size
    14t/Bottle
  • Strength
    17.7mg&26.5mg
  • Compositon
    Quizartinib
  • Treatment
    Acute Myeloid Leukemia,AML
  • Form
    Tablet
  • Brand
    LuciQuiza
  • Quantity Unit
    17.7mg*14t/Box&26.5mg*14t/Box
  • Manufacturer
    Lucius Pharmaceuticals (Lao) Co.,Ltd

About Quizartinib

Quizartinib is an anti-cancer medication used for the treatment of acute myeloid leukemia. It is a small molecule receptor tyrosine kinase inhibitor. Its molecular target is FLT3, also known as CD135 which is a proto-oncogene.FLT3 mutations are among the most common mutations in acute myeloid leukemia due to internal tandem duplication of FLT3, and the presence of this mutation is a marker of adverse outcome.

Acute Myeloid Leukemia

Indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test

Each cycle is 28 days

If patient proceeds to hematopoietic stem cell transplantation (HSCT), stop quizartinib 7 days before starting conditioning regimen

Induction

May receive up to 2 cycles of induction

Quizartinib 35.4 mg PO qDay on Days 8-21, PLUS

7 + 3 regimen (cytarabine 100 or 200 mg/m2/day IV on Days 1-7 plus daunorubicin 60 mg/m2/day IV or idarubicin 12 mg/m2/day IV on Days 1-3)

  • Optional second induction
    • Quizartinib plus 7 + 3 or 5 + 2 regimen (5 days cytarabine plus 2 days daunorubicin or idarubicin)
    • If 5 + 2 regimen administered as second induction cycle, administer quizartinib on Days 6-19

Consolidation

  • Quizartinib 35.4 mg PO qDay on Days 6-19, PLUS
  • Cytarabine 1.5-3 g/m2 q12hr on Days 1, 3, and 5 for up to 4 cycles

Maintenance

  • Quizartinib 26.5 mg PO qDay on Days 1-14 of the first cycle if QTcF ≤450 ms
  • Increase dose to 53 mg once daily on Day 15 of first cycle if QTcF ≤450 ms
  • Maintain 26.5 mg PO qDay if QTcF >500 ms was observed during induction or consolidation
  • Duration is once daily with no break between cycles for up to 36 cycles

Link

Poster

Top